Universal vaccine! - Asian Journal News

Universal vaccine! - Asian Journal News

MAN’S ingenuity and cleverness are once again making a quantum leap for the betterment of mankind. And progress promotes even greater and more wonderful progress. The United States  National Institute of Health and the Department of Health and Human Services announced the development of a “next-generation, universal vaccine platform,” intended to create a universal COVID-19 and influenza one-shot-for-both vaccine that…

Moderna's combo Covid and flu mRNA shot outperforms current vaccines in large trial

Moderna’s combined Covid and flu shot outperformed the existing standalone vaccines for both viruses, according to the results of a phase 3 clinical trial published Wednesday in the Journal of the American Medical Association.

The technology that marked a turning point in the coronavirus pandemic, the messenger RNA, continues to conquer territories in the vaccine ecosystem. A new research, published this Wednesday in Jama magazine, has supported the path to optimize vaccination against two large respiratory viruses: influenzavirus and covid SARS-CoV-2. The trial, developed by the pharmaceutical company Moderna, has found that its combined vaccine achieves an immune re…

Influenza COVID-19 Combination Vaccine Induces Higher Immune Response Than Standalone Immunizations

In a large study, Moderna’s investigational vaccine, mRNA-1083, was shown to have noninferiority to other vaccines, and had an acceptable tolerability and safety profile.

FDA will convene vaccine advisors to discuss Covid strain updates

FDA advisors will meet later this month to discuss which Covid-19 strain vaccine makers should target ahead of the the fall and winter, when infections tend to spike. The May 22 meeting, disclosed in a ...

Rewrite Immunogenicity and safety of influenza and COVID-19 multicomponent

About The Study: In this phase 3 study, mRNA-1083, an investigational, multicomponent vaccine against seasonal influenza and SARS-CoV-2, met noninferiority criteria and induced higher immune responses than recommended standard care influenza (standard and high dose) and COVID-19 vaccines against all 4 influenza strains (among those ages 50-64), the 3 clinically relevant influenza strains (among those age 65 and older), and SARS-CoV-2 (all ages),…